PLEASANT trial: to determine whether an NHS delivered public health intervention reduces exacerbation of asthma, and unscheduled NHS contacts, in school aged children associated with the return to school in September

Conditions

Childhood asthma Respiratory Asthma

Steven A Julious, Michelle J Horspool, Sarah Davis, Matthew Franklin, W Henry Smithson et al. (10 authors)

BMJ Open2018-04-0110 citations

10.1136/bmjopen-2017-017367

Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study.

Franklin M, Davis S, Horspool M, Kua WS, Julious S.

2017-05-0111 citations

10.1007/s40273-016-0484-y

PLEASANT: Preventing and Lessening Exacerbations of Asthma in School-age children Associated with a New Term - a cluster randomised controlled trial and economic evaluation.

Julious SA, Horspool MJ, Davis S, Bradburn M, Norman P, Shephard N, Cooper CL, Smithson WH, Boote J, Elphick H, Loban A, Franklin M, Kua WS, May R, Campbell J, Williams R, Rex S, Bortolami O.

2016-12-0115 citations

10.3310/hta20930

Preventing and lessening exacerbations of asthma in school-age children associated with a new term (PLEASANT): study protocol for a cluster randomised control trial.

Horspool MJ, Julious SA, Boote J, Bradburn MJ, Cooper CL, Davis S, Elphick H, Norman P, Smithson WH, VanStaa T.

2013-09-1616 citations

10.1186/1745-6215-14-297

Interventions

70 GP practices undertaking the intervention and 70 control practices of ?usual care?. Postal intervention sent to all school aged children with asthma at the start of the school holidays in July vs

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Children: 1. Between 4 and 16 years of age as of 01/09/2012 2. With a coded diagnosis of asthma 3. Who have been prescribed asthma medication in the previous 12 months

Exclusion criteria

Exclusion criteria: Children: 1. Aged 4 and under and 16 and over years of age as of 01/09/2012 2. Who are not considered appropriate for this intervention by their GP 3. With asthma who are not receiving asthma medication 4. With co-existing neoplastic disease

Design outcomes

Primary

Measure	Time frame
The proportion of patients aged between 5-16 who have an unscheduled medical contact in September	—

Secondary

Measure	Time frame
1. The proportion of patients who have an unscheduled medical contact in the period September-December 2. The total number of medical contacts (scheduled and unscheduled) per patient in September and in the period September-December 3. The time to first unscheduled medical contact in September and in the period September-December 4. The proportion of patients who have a medical contact (either scheduled or unscheduled) in September and in the period September-December 5. The total number of medical contacts (either scheduled and unscheduled) per patient in September and in the period September-December 6. The time to first medical contact in September and in the period September-December 7. The proportion of patients who have an unscheduled medical contact in September and in the period September-December associated with a respiratory diagnosis 8. The number of unscheduled medical contacts per patient in September and in the period September-December associated with a respiratory diagnosis 10. The number of prescriptions per patient in the month of August 11. The number of prescriptions in the 12 months following the intervention 12. The proportion of patients who have a scheduled medical contact (for example asthma review) in August 13. The proportion of patients who have a scheduled medical contact (for example asthma review) in the 12 months following the intervention. The above analyses will be undertaken on patients aged 5-16, since asthma is difficult to diagnose in children below this age; patients aged <5 will be analysed separately to these.	—

Measure

Time frame

1. The proportion of patients who have an unscheduled medical contact in the period September-December 2. The total number of medical contacts (scheduled and unscheduled) per patient in September and in the period September-December 3. The time to first unscheduled medical contact in September and in the period September-December 4. The proportion of patients who have a medical contact (either scheduled or unscheduled) in September and in the period September-December 5. The total number of medical contacts (either scheduled and unscheduled) per patient in September and in the period September-December 6. The time to first medical contact in September and in the period September-December 7. The proportion of patients who have an unscheduled medical contact in September and in the period September-December associated with a respiratory diagnosis 8. The number of unscheduled medical contacts per patient in September and in the period September-December associated with a respiratory diagnosis 10. The number of prescriptions per patient in the month of August 11. The number of prescriptions in the 12 months following the intervention 12. The proportion of patients who have a scheduled medical contact (for example asthma review) in August 13. The proportion of patients who have a scheduled medical contact (for example asthma review) in the 12 months following the intervention. The above analyses will be undertaken on patients aged 5-16, since asthma is difficult to diagnose in children below this age; patients aged <5 will be analysed separately to these.

—

Countries

United Kingdom

Outcome results

None listed